Men's Health News

RSS

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Women more likely to develop a disability than men

According to a new study released by The State Farm Center for Women and Financial Services at The American College, women – whether they're working or a stay-at-home mom, single or married – women are most at risk both physically and financially when it comes to disability.

5 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Liver metastases predicts shorter overall survival in men with mCRPC

Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2012

Moderately higher risk of stroke for women than men with irregular heart rhythm

Women with irregular heart rhythm (known as atrial fibrillation) have a moderately increased risk of stroke compared with men, suggesting that female sex should be considered when making decisions about anti-clotting treatment, finds a study published on bmj.com today.

1 Jun 2012

Large-scale, coordinated effort needed to stop increase in HIV transmission among MSM in China

HIV transmission in China is increasing faster among men who have sex with men (MSM) than in any other population, a trend that "cannot continue," a group of researchers working in China write in a Nature commentary, adding, "Policymakers, public health researchers, clinicians, educators, community leaders and other stakeholders in China must come together to educate everyone, and gay men in particular, about HIV prevention and treatment -- before any more people become infected as a result of ignorance and fear."

1 Jun 2012

Men are not better at quitting smoking than women according to new study

There is “no convincing evidence” that men are better than women at quitting smoking, finds research published online in Tobacco Control.

31 May 2012

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

For many prostate cancer patients, new guidance is confusing

The recommendation that fewer men get screened for the disease goes against what many people believe should be appropriate, NPR reports.

30 May 2012

IU scientists focus on health issues and behaviors specific to bisexual men and women

Bisexuality, often stigmatized, typically has been lumped with homosexuality in previous public health research. But when Indiana University scientists recently focused on the health issues and behaviors specific to behaviorally bisexual men and women, they found tremendous variety, and that commonly used labels, such as heterosexual and homosexual, can sometimes do more harm than good.

30 May 2012

Cabazitaxel offers added benefit for men with metastatic prostate cancer

Cabazitaxel has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.

30 May 2012

PKCZ protein could serve as new treatment target for prostate cancer

A newly-discovered protein found only in prostate cancer cells could be used as a marker of the disease and offer a new treatment target, according to a study in the British Journal of Cancer.

30 May 2012

Women and men not receiving effective diagnostic testing and treatments for osteoporosis

Women and men are not receiving effective diagnostic testing and treatments of osteoporosis, a life threatening condition affecting millions of Americans, according to an expert today at the American Association of Clinical Endocrinologists (AACE) 21st Annual Meeting & Clinical Congress in Philadelphia.

28 May 2012

X-chromosome involved in development of bowel cancer

Scientists have shown for the first time that one of the sex chromosomes is involved in the development of a cancer that can afflict both genders, according to a Cancer Research UK-funded study in Nature Genetics.

28 May 2012

Hearing loss linked to several chronic diseases

The Better Hearing Institute (BHI) is raising awareness of the link between hearing loss and some chronic diseases during National Men's Health Week (June 11 – 17).

25 May 2012